Use and Outcomes of Triple Antithrombotic Therapy with Non-Vitamin K Antagonists in Patients with Atrial Fibrillation Undergoing Percutaneous Coronary Intervention

• Published in: The American journal of the medical sciences Vol. 358; no. 2; p. 95
• Main Authors: Casamira, Núria, García-Camarero, Tamara, Montoro-Ronsano, J Bruno, Veiga, Gabriela, Del Blanco, Bruno García, De La Torre, José María, Gordon, Blanca, García-Dorado, David, Sambola, Antonia
• Format: Journal Article
• Language: English
• Published: United States 01.08.2019
• Subjects: Aged; Anticoagulants - administration & dosage; Anticoagulants - therapeutic use; Atrial Fibrillation - surgery; Drug Therapy, Combination; Female; Fibrinolytic Agents - administration & dosage; Fibrinolytic Agents - therapeutic use; Hemorrhage - epidemiology; Hemorrhage - prevention & control; Humans; Incidence; Male; Percutaneous Coronary Intervention; Retrospective Studies; Vitamin K - antagonists & inhibitors; Anticoagulant; Atrial fibrillation; Non-vitamin K antagonist oral anticoagulants; Bleeding; Percutaneous Coronary Intervention
• ISSN: 1538-2990
• DOI: 10.1016/j.amjms.2019.03.009

Triple antithrombotic therapy (TT) is recommended for patients with nonvalvular atrial fibrillation (AF) undergoing percutaneous coronary intervention (PCI). However, there is a lack of comparative data in a real-world clinical setting between non-vitamin K antagonist oral anticoagulants (NOAC) and vitamin K antagonists (VKA). The aim of this study was to compare the safety and efficacy of TT with NOAC or VKA after PCI in patients with AF at 1-year of follow-up. This was an observational retrospective study in 2 tertiary care hospitals during 2013-2016. Patients with indication for anticoagulation due to AF from an initial registry of 5,269 patients undergoing PCI were identified. Safety primary endpoint was the occurrence of major bleeding events as defined by Bleeding Academic Consortium (BARC ≥ 3). The primary efficacy endpoint was defined as major adverse cardiovascular events (MACE). A total of 187 consecutive patients on TT were identified: 45.4% of were discharged on NOAC and 54.6% on VKA. Patients who received VKA presented more comorbidities and had a higher bleeding risk than those who received NOACs. Major bleeding events occurred in 17 patients (9%), with a higher rate in the VKA group (3.5% vs. 13% confidence interval, 0.19-0.86, P = 0.02). There were no differences in the rates of major adverse cardiovascular events, stroke or net clinical benefit. In this real-world study, patients with AF undergoing PCI treated on NOAC-based TT showed lower bleeding rates than those on VKA, with a lower rate of major bleeding events, while efficacy was similar between groups.